These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

105 related articles for article (PubMed ID: 12393711)

  • 1. Human T cells resistant to complement lysis by bivalent antibody can be efficiently lysed by dimers of monovalent antibody.
    Nielsen SU; Routledge EG
    Blood; 2002 Dec; 100(12):4067-73. PubMed ID: 12393711
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The improved lytic function and in vivo efficacy of monovalent monoclonal CD3 antibodies.
    Clark M; Bindon C; Dyer M; Friend P; Hale G; Cobbold S; Calne R; Waldmann H
    Eur J Immunol; 1989 Feb; 19(2):381-8. PubMed ID: 2522881
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A humanized monovalent CD3 antibody which can activate homologous complement.
    Routledge EG; Lloyd I; Gorman SD; Clark M; Waldmann H
    Eur J Immunol; 1991 Nov; 21(11):2717-25. PubMed ID: 1834468
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficiency of T cell triggering by anti-CD3 monoclonal antibodies (mAb) with potential usefulness in bispecific mAb generation.
    Jacobs N; Mazzoni A; Mezzanzanica D; Negri DR; Valota O; Colnaghi MI; Moutschen MP; Boniver J; Canevari S
    Cancer Immunol Immunother; 1997 Jul; 44(5):257-64. PubMed ID: 9247560
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The mechanism of anti-CD3 monoclonal antibodies. Mediation of cytolysis by inter-T cell bridging.
    Wong JT; Eylath AA; Ghobrial I; Colvin RB
    Transplantation; 1990 Oct; 50(4):683-9. PubMed ID: 2145670
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Lysis of human tumor cell lines by canine complement plus monoclonal antiganglioside antibodies or natural canine xenoantibodies.
    Helfand SC; Hank JA; Gan J; Sondel PM
    Cell Immunol; 1996 Jan; 167(1):99-107. PubMed ID: 8548851
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Activation of the human classical complement pathway by a mouse monoclonal hybrid IgG1-2a monovalent anti-TNP antibody bound to TNP-conjugated cells.
    Couderc J; Kazatchkine MD; Ventura M; Duc HT; Maillet F; Thobie N; Liacopoulos P
    J Immunol; 1985 Jan; 134(1):486-91. PubMed ID: 3917282
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Chimeric bispecific OC/TR monoclonal antibody mediates lysis of tumor cells expressing the folate-binding protein (MOv18) and displays decreased immunogenicity in patients.
    Luiten RM; Warnaar SO; Sanborn D; Lamers CH; Bolhuis RL; Litvinov SV; Zurawski VR; Coney LR
    J Immunother; 1997 Nov; 20(6):496-504. PubMed ID: 9409456
    [TBL] [Abstract][Full Text] [Related]  

  • 9. CD8+ T cells lyse autologous monocytes in the presence of anti-CD3 monoclonal antibody: association with interleukin-1 production.
    Itoh K; Balch CM; Trial J; Platsoucas CD
    Cell Immunol; 1988 Jul; 114(2):257-71. PubMed ID: 3260540
    [TBL] [Abstract][Full Text] [Related]  

  • 10. p40, a novel surface molecule involved in the regulation of the non-major histocompatibility complex-restricted cytolytic activity in humans.
    Poggi A; Pella N; Morelli L; Spada F; Revello V; Sivori S; Augugliaro R; Moretta L; Moretta A
    Eur J Immunol; 1995 Feb; 25(2):369-76. PubMed ID: 7875198
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Generation of chimeric bispecific G250/anti-CD3 monoclonal antibody, a tool to combat renal cell carcinoma.
    Luiten RM; Coney LR; Fleuren GJ; Warnaar SO; Litvinov SV
    Br J Cancer; 1996 Sep; 74(5):735-44. PubMed ID: 8795576
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Complement-mediated lysis by anti-CD20 mAb correlates with segregation into lipid rafts.
    Cragg MS; Morgan SM; Chan HT; Morgan BP; Filatov AV; Johnson PW; French RR; Glennie MJ
    Blood; 2003 Feb; 101(3):1045-52. PubMed ID: 12393541
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Monoclonal antibody homodimers: enhanced antitumor activity in nude mice.
    Wolff EA; Schreiber GJ; Cosand WL; Raff HV
    Cancer Res; 1993 Jun; 53(11):2560-5. PubMed ID: 8495420
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Preparation and properties of FabIgG, a chimeric univalent antibody designed to attack tumour cells.
    Stevenson GT; Glennie MJ; Paul FE; Stevenson FK; Watts HF; Wyeth P
    Biosci Rep; 1985; 5(10-11):991-8. PubMed ID: 3879458
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Chemically self-assembled antibody nanorings (CSANs): design and characterization of an anti-CD3 IgM biomimetic.
    Li Q; So CR; Fegan A; Cody V; Sarikaya M; Vallera DA; Wagner CR
    J Am Chem Soc; 2010 Dec; 132(48):17247-57. PubMed ID: 21077608
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Heparin inhibition of antibody-dependent complement-mediated lysis.
    Wesolowski J; Ault K; Houghton R; Parkman R
    Exp Hematol; 1984 Oct; 12(9):700-5. PubMed ID: 6237929
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Characterization of mAb dimers reveals predominant dimer forms common in therapeutic mAbs.
    Plath F; Ringler P; Graff-Meyer A; Stahlberg H; Lauer ME; Rufer AC; Graewert MA; Svergun D; Gellermann G; Finkler C; Stracke JO; Koulov A; Schnaible V
    MAbs; 2016 Jul; 8(5):928-40. PubMed ID: 27031922
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Regulation of cytolytic activity in CD3- and CD3+ killer cell clones by monoclonal antibodies (anti-CD16, anti-CD2, anti-CD3) depends on subclass specificity of target cell IgG-FcR.
    van de Griend RJ; Bolhuis RL; Stoter G; Roozemond RC
    J Immunol; 1987 May; 138(10):3137-44. PubMed ID: 2952709
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A new recombinant single chain trispecific antibody recruits T lymphocytes to kill CEA (carcinoma embryonic antigen) positive tumor cells in vitro efficiently.
    Wang XB; Zhao BF; Zhao Q; Piao JH; Liu J; Lin Q; Huang HL
    J Biochem; 2004 Apr; 135(4):555-65. PubMed ID: 15115782
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Expression of HLA-C molecules confers target cell resistance to some non-major histocompatibility complex-restricted T cells in a manner analogous to allospecific natural killer cells.
    Falk CS; Steinle A; Schendel DJ
    J Exp Med; 1995 Oct; 182(4):1005-18. PubMed ID: 7561674
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.